培美曲塞联合顺铂一线治疗晚期非小细胞肺癌34例临床疗效和安全性观察

An investigation on clinical effect and safety of pemetrexed combined with cisplatin advanced non small cell lung cancer of 34 cases

目的观察培美曲塞联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的近期疗效及毒副反应。方法 34例晚期肺癌患者采用培美曲塞联合顺铂治疗方案,其中培美曲塞500 mg/m2,顺铂75 mg/m2。结果 34例患者有效率(CR+PR)为38.24%,疾病控制率(CR+PR+SD)为79.4%,主要毒性反髓抑应为骨制,消化道反应,皮疹等。结论培美曲塞联合顺铂一线治疗晚期非小细胞肺癌疗效较好,毒性反应较低,值得临床推广使用。

Objective To investigate the clinical effect and safety of pemetrexed joint with cisplatin for the patients with advanced non-small cell lung cancer （ NSCLC） .Methods 34 patients with NSCLC received a treatment program with pemetrexed and cisplatin , the dose of pemetrexed was 500mg/m2, and cisplatin was 75mg/m2 .Results The efficiency （ CR＋PR） of 34 patients was 38.24%, the disease control rate （ CR＋PR＋SD） was 79.4%, and the mainly adverse reactions were bone marrow suppression , gastrointestinal reactions , skin rash.Conclusions The pemetrexed joint with cisplatin has a clear efficacy and slight toxicity for NSCLC , worthy of clinical use .